The Fly | LGVN

Proprietary Cell Therapy Technology: Longeveron utilizes a proprietary allogeneic mesenchymal stem cell (LMSC) platform, offering a unique "off-the-shelf" solution that simplifies administration compared to autologous therapies.

Diverse Clinical Pipeline: The company is investigating its lead product, LMSCs, across multiple high-impact indications such as Hypoplastic Left Heart Syndrome, Alzheimer's Disease, and Frailty, diversifying market potential.

Expedited Regulatory Pathways: Longeveron has secured Fast Track designation from the FDA for its HLHS program, potentially accelerating the development and review process for this critical indication.

Unsuccessful Clinical Trials: Lomecel-B may not demonstrate efficacy or safety in ongoing or future clinical trials, halting its development.

Failure to Obtain Regulatory Approval: Even with positive trial data, Longeveron may not receive necessary regulatory approvals from bodies like the FDA for its product candidates.

Insufficient Capital and Funding: The company may be unable to raise sufficient additional capital to fund its operations and complete the development of its product candidates.

Unsuccessful Clinical Trials: Lomecel-B may not demonstrate efficacy or safety in ongoing or future clinical trials, halting its development.

Failure to Obtain Regulatory Approval: Even with positive trial data, Longeveron may not receive necessary regulatory approvals from bodies like the FDA for its product candidates.

Insufficient Capital and Funding: The company may be unable to raise sufficient additional capital to fund its operations and complete the development of its product candidates.

Today

Longeveron appoints Marie Washburn CFO